Ronen O, Robbins KT, Olsen KD, Shaha AR, Randolph GW, Nixon IJ, Zafereo ME , Hartl DM, Kowalski LP, Rodrigo JP, Coca-Pelaz A, Mkitie AA, Vander Poorten V, Sanabria A, Angelos P, Rinaldo A, Ferlito A
The FDA has approved several GLP-1 receptor agonists specifically for chronic weight management, marking a meaningful milestone in obesity medicine
WARNINGS Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, laryngeal edema, and bronchospasm have been reported following levocarnitine administration, mostly in patients with end-stage renal disease (ESRD) who are undergoing dialysis
To advance translational applications, future studies should focus on: (1) transforming dynamic biomarkers into clinical decision-making tools, such as evaluating early changes in circulating mitochondrial-derived vesicles or oxidative stress markers (e.g., 8isoprostaglandin F2 (8-iso-PGF2))to predict subsequent biochemical and histological responses
Prioritize a balanced perspective when exploring alternative options for thyroid health
It is a key point to consider in AIM-based kidney care